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A SUMMARy Of 3-yEAR OUTCOMES
INTRODUCTION
The Research Outcome Study in Ireland (ROSIE) is the first national, prospective, longitudinal, multi-site drug treatment 
outcome study in the country. The National Advisory Committee on Drugs (NACD) commissioned this research in 
2002 as required by the National Drugs Strategy Action 99. The aim of the study was to recruit and follow opiate users 
entering treatment over a period of time, documenting the changes observed. The contract was awarded to Dr. Catherine 
Comiskey and NUI Maynooth in 2002.
The study recruited 404 opiate users entering treatment. Outcomes at 3-years for drug use, involvement in crime, 
injecting-related behaviour, physical and mental health, among others, are presented in this paper. Statistically significant 
differences are given emphasis in this document. 
KEy MESSAGES
(Only statistically significant reductions are noted below, 
figures rounded) 
l 404 opiate users were recruited at treatment intake:  
97% (n=392) were located at 3-years and  
88% (n=357) successfully completed their final interview.
l 1.5% (n=6) of the study population had died at the 3-year 
follow-up interview stage.
l 69% (n=246) were in some form of drug treatment at 3-years. 
l 29% (n=105) were abstinent from all illegal drugs at 3-years.
l Heroin use reduced from 77% at intake to 46% at 3-years.
l Significant reductions were observed for other drug use  
at 3-years.
l Injecting drug use (heroin) reduced from 42% at intake  
to 25% at 3-years.
l Injecting drug use (cocaine) reduced from 21% at intake  
to 10% at 3-years.
l Selling or dealing drugs reduced from 30% at intake to 13%  
at 3-years.
l Significant improvements in physical and mental health 
symptoms were observed.
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SUMMARy ALL OUTCOMES
DRUG USE OUTCOMES
l	 Heroin use: There was a reduction in the overall 
percentage of individuals reporting heroin use, from 76.9% 
at intake to 46.2% at 3-years follow-up. The frequency  
of heroin use was significantly reduced from 40.1 days  
in the last 90 days at treatment at intake, to 20.7 days  
at 3-years. The amount of heroin used also reduced 
significantly between intake (0.6g) and 3-years (0.2g).
l	 Other drug use: Reductions in the reported use of all 
target drugs, non-prescribed methadone, non-prescribed 
benzodiazepines, cocaine (including crack), cannabis and 
alcohol were seen at 3-years. 
• Reported use of cannabis reduced significantly from 
64.1% at treatment intake to 48.9% at 3-years.
• Reported use of cocaine (including crack) reduced 
significantly from 48.3% at treatment intake to 22.5% 
at 3-years.
• Reported use of non-prescribed benzodiazepines 
reduced significantly from 44.3% at treatment intake to 
31.7% at 3-year follow-up.
• Reported use of non-prescribed methadone reduced 
significantly from 40.6% at treatment intake to 13.8% 
at 3-years.
• Reported use of alcohol reduced significantly from 
53.8% at treatment intake to 44.2% at 3-years.
• Reductions in the frequency (mean days) of use of all 
target drugs were observed between intake and 3-years.
• The overall percentage of individuals reporting polydrug 
use1 decreased significantly from 76.2% at treatment 
intake to 46.5% at 3-years.
l	 Drug abstinence: A significant increase in the 
percentage of individuals reporting abstinence from all 
drugs (excluding alcohol and prescribed methadone) was 
observed between intake (9.3%) and 3-years (29.4%).
INVOLVEMENT IN CRIME OUTCOMES
l	 Within the 12 crime variables measured, there were 
significant reductions in the proportion of participants 
reporting involvement in 10 of the 12 categories of crime 
between intake and 3-years.
RISK BEHAVIOUR OUTCOMES
l	 Significant improvements were evident in the proportions 
injecting any drug, the number of days injecting any drug, 
and the number of times injecting any drug on a typical 
drug-taking day in the last three months, between intake 
and 3-years.
l	 At treatment intake, participants reported low rates of 
borrowing and lending of used injecting equipment.  
There were no significant changes in these behaviours  
at 3-years.
l	 There were no significant changes in overdose rates.
PHySICAL AND MENTAL HEALTH OUTCOMES
l	 A significant reduction in five of the ten physical health 
symptoms was observed between intake and 3-years.
l	 No significant reductions were observed in any of the five 
anxiety symptoms between intake and 3-years.
l	 A significant reduction in three of the five depressive 
symptoms was observed between intake and 3-years.
TREATMENT STATUS
l	 68.9% were in some form of treatment at 3-years.
EMPLOyMENT AND TRAINING
l	 Proportions currently working, employed at some time in 
the last three months, and on a training course over the 
last six months all increased significantly between intake 
and 3-years. 
l	 The proportion who described themselves as usually not 
working fell significantly between intake and 3-years.
ACCOMMODATION
l	 The proportion living in the family home decreased 
significantly between intake and 3-years, while the 
proportion owning their own house or flat, or in rental 
accommodation, increased significantly between intake 
and 3-years.
l	 The proportion in a drug treatment residence decreased 
significantly between intake and 3-years.
l	 The proportion in insecure accommodation (including 
participants living in hostels, shelters, B&B’s or with no 
fixed abode) decreased significantly between intake and 
3-years.
CONTACT WITH SERVICES
l	 Contact with two of the four health services increased 
significantly between intake and 3-years.
l	 Of the four social support services investigated, use of 
two of the services, one regarding employment, training 
or education and the other regarding housing, increased 
significantly between intake and 3-years.
1  The definition of polydrug use is concurrent drug use, meaning at least two substances are used during the same time period (NACD, 2007). We define 
polydrug use as the use of two or more illegal substances in the last 90 days, the time period for which drug use data was collected.
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METHODOLOGy
1. STUDy DESIGN
ROSIE is a longitudinal observational study, which follows 
participants from the point of commencing a new treatment 
episode (treatment intake) and monitors progress at time 
anchored points; at intake, then at 1-year and 3-years 
after treatment intake. Between September 2003 and July 
2004, the ROSIE study recruited 404 opiate users. The 
majority entered one of three index treatments: methadone 
maintenance/reduction (53.2%, n=215), structured 
detoxification (20%, n=81) and abstinence-based treatment 
(20.3%, n=82) and the remainder were recruited from 
needle-exchanges (6.4%, n=26). These modalities were part 
of the tender brief from the NACD as they were considered 
to represent the most widely implemented interventions for 
opiate users in Ireland.
The 404 ROSIE study participants were recruited from both 
inpatient (hospitals, residential programmes and prisons) 
and outpatient settings (community-based clinics, health 
board clinics and GP’s). Participants had to be over 18 years, 
commencing a new treatment episode, prepared to consent to 
the tracking/follow-up procedures, and willing to provide locator 
information. Treatment agencies participating in the study were 
purposively (not randomly) sampled to reflect drug treatment 
in Ireland, and the known geographical spread of provision and 
range of services. In total, 44 agencies providing approximately 
54 services located in rural, urban and inner-city areas of Ireland 
were involved in the study. In addition, a Research Advisory 
Group was established by the NACD to support and monitor 
the research project. 
Participants were interviewed at the three time periods using 
a pre-prepared interview schedule, which examined key 
outcome measures including:
l	 Drug use (drug type, frequency, and quantity of drug use);
l	 General health (a 10-point physical and mental health 
assessment);
l	 Social functioning (employment, accommodation, 
involvement in crime);
l	 Harm (injecting behaviour & experience of overdose); and
l	 Mortality (participant/contact feedback and checking 
non followed-up participants against the General Death 
Register).
In addition to a lifetime measure, measures were taken for 
behaviours in the 90 days preceding interviews, except for 
injecting related risk behaviour variables where use in the last 
30 days was used. Individuals were asked about their use of 
16 substances. This document focuses on the seven most 
frequently reported problem drugs – referred to as target 
drugs (heroin, non-prescribed methadone, non-prescribed 
benzodiazepines, cocaine powder, crack cocaine, cannabis 
and alcohol)2 and reports changes in use patterns at 3-years. 
For more detailed information on lifetime use and use at 
intake, see Cox & Comiskey (2007) and the baseline ROSIE 
report (http://www.nacd.ie/publications/treatment_rosie_
summary.html). 
2. fOLLOW-UP
Follow-up of participants was assisted by the provision of 
at least four contacts (locator information) for each person 
(including a drug treatment contact, family member, GP & 
others). A small remuneration was provided at 1-year and  
at 3-year follow-up to acknowledge the ongoing participation 
of the individual in the study. 
As a result of extensive tracking efforts, 97% of all original 
participants were located at 3-year follow-up (n=392) 
and 88% (n=357) of participants successfully completed 
interviews. This is an improvement on the 12-month follow-
up where 75% (n=305) of the original cohort completed  
full interviews. At 3-years, a total of 3.5% (n=14) of 
participants did not wish to be interviewed, 3% (n=12)  
were not located and 1.5% (n=6) of participants were 
deceased, with 0.2% (n=1) in a coma. 3.5% (n=14) 
were located but not interviewed and of these participants, 
four individuals were living in another country and eight 
individuals were on a methadone programme. None of  
these individuals were in prison. 
The follow-up rate in the study for participants who were 
interviewed and the location rate for those who were either 
located or interviewed at the 3-year follow-up time point 
exceeded all international standards achieved to date and 
completely reversed the usual trend of decreasing follow-up 
rates as time progresses. 
Within ROSIE, the 3-year mortality rate was 1.5% (95%  
C.I.3 : 0.5% - 3.2%). Six of the 404 participants died 
between the start of recruitment in September 2003 and  
the end of 3-year follow-up interview period in July 2007. 
Two of these deaths occurred within the 1-year follow-up 
period. The mortality rate for the population (2/404) at  
1-year was 0.5% (95% C.I.: 0.06% - 1.78%). 
3. STUDy LIMITATIONS
1. Although the findings presented here highlight positive 
outcomes for study participants, they do not indicate a 
direct causal relationship between the treatment received 
and the outcomes observed.
2. The study did not randomly allocate participants to 
treatment settings/modality or employ a control group 
(drug users with similar profile not attending the index 
treatment).
3. Any individual behaviour change is the result of the 
interaction of three factors, the person, the environment 
and the intervention, all of which can influence outcomes 
but which could not be controlled for in this study.
2  In some instances, where appropriate, data with respect to cocaine powder and crack cocaine were combined for analysis.
3 C.I.: Confidence Interval.
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4. UNDERSTANDING THIS PAPER
The reader should be aware that the data presented in 
this paper include all valid responses provided by the 
cohorts who completed the intake and the 3-year follow-
up interviews, while the statistical comparisons are made 
on matched data or dependent pairs, i.e., only individuals 
who provided valid answers to each question at each of 
the two time points under comparison were included in 
analysis. Missing data were handled by excluding the cases 
from the particular analysis4. In terms of presenting statistical 
comparisons, data presented with an asterisk(*) subscript 
are statistically significant. Changes in all categorical variables 
were analysed using the McNemar test. Paired sample t-tests 
were performed when comparing sample means at two time 
points. Statistical significance can only be stated when tests 
have been carried out on the data to establish the degree of 
confidence with which it can be inferred that the differences 
in the observed findings are true and not due to sampling or 
other error. This is reported at a 5% level of probability, that 
is, a p-value of 0.05 or less is used for statistical significance.
Readers will observe some data changes from previous 
publications for intake numbers because the data are paired. 
As more people were interviewed at 3-years than at 1-year 
the baseline numbers at intake may differ for the various 
categories under observation.
International drug treatment outcome studies typically 
measure levels of drug use, health, crime, mortality and social 
functioning variables to monitor the impact of treatments for 
problem drug use (see e.g. Gossop et al, 2002; Gossop et 
al, 2003; Hubbard et al, 2003; Darke et al, 2006; Schifano, 
2006; Teesson et al, 2006).
Within this findings paper, in order to keep tables of data 
clear and easy to read, changes from intake to 3-years for 
males and for females are not reported. Details on the 
effects of gender on outcomes observed at 3-years will 
be presented in the forthcoming Findings on predictors 
of outcomes. In addition gender is also addressed within 
Findings on polydrug use. 
4 The percentage totals presented in Tables 1-15 are calculated on the basis of valid responses. 
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DRUG USE OUTCOMES
There are a variety of different ways drug use outcomes can 
be measured. Analysis was carried out to examine changes in:
n	 The percentage of individuals reporting the use of each  
drug type.
n	 Drug using frequency (mean number of drug-using days 
over the previous 90 days).
n	 Average quantity of each drug consumed on a typical  
drug-using day.
n	 Drug abstinence rates.
THE PERCENTAGE Of INDIVIDUALS 
REPORTING THE USE Of EACH DRUG TyPE
Table 1 shows the proportions using each target drug 
as reported at treatment intake and at 3-year follow-up. 
Reductions in the proportions using each drug, proportions 
using alcohol and proportions engaging in polydrug use 
between treatment intake and 3-year follow-up were all found 
to be significant. 
Table 1:  Drug use at treatment intake and 3-years
Drug use in last  
90 days
Intake 3-years
% n % n
Heroin 76.9 306 46.2* 165
Cannabis 64.1 243 48.9* 174
Cocaine  
(including crack)
48.3 195 22.5* 80
1Benzodiazepines 44.3 174 31.7* 113
2Methadone 40.6 162 13.8* 49
Alcohol 53.8 204 44.2* 157
3Polydrug use 76.2 308 46.5* 166
1 Refers to non-prescribed benzodiazepines.  
2 Refers to non-prescribed methadone.  
3 Polydrug use defined as using two or more illegal drugs  
in the last 90 days.
* denotes statistical significance.
Table 2 displays the mean number of days on which each drug 
was used as reported at treatment intake and at 3-years. Analysis 
revealed significant reductions in the mean days used between 
treatment intake and 3-year follow-up.
Table 2:  Drug using days at treatment intake  
and 3-years
Mean days used  
in last 90 days
Intake 3-years
Mean (s.d.) Mean (s.d.)
Heroin 40.1 (35.8) 20.7 (32.8) *
Cannabis 39.0 (40.1) 25.1 (36.1) *
1Benzodiazepines 15.5 (29.1)  9.4 (22.8) *
2Methadone 11.6 (23.2)  2.6 (10.8) *
Cocaine (including crack)  8.7 (18.9)  3.6 (12.8) *
Alcohol 13.3 (23.7) 10.9 (22.5) *
1 Refers to non-prescribed benzodiazepines.
2 Refers to non-prescribed methadone.
* denotes statistical significance.
Table 3 illustrates the mean quantity of each drug that was 
consumed on a typical using day as reported at treatment 
intake and 3-year follow-up. Analysis revealed a significant 
reduction in the average quantity of all drugs consumed 
between treatment intake and 3-years, with the exception  
of benzodiazepines.
Table 3:  Mean quantity of drugs consumed at 
treatment intake and 3-years
Mean amounts used  
per day in last 90 days
Intake 3-years
Mean (s.d.) Mean (s.d.)
Heroin (grams) 0.6 (0.8) 0.2 (0.4) *
Cannabis (joints) 7.7 (16.5) 3.7 (11.1) *
Cocaine excluding crack 
(grams)
0.9 (2.4) 0.3 (0.8) *
1Benzodiazepines (mg) 41.9 (105.5) 39.9 (136.8)
2Methadone (ml) 23.3 (37.7) 9.1 (29.6) *
Alcohol (units) 9.1 (15.2) 5.8 (9.9) *
1 Refers to non-prescribed benzodiazepines.
2 Refers to non-prescribed methadone.
* denotes statistical significance.
Crack cocaine was excluded due to inconsistency in how the data  
was reported.
These cost figures are based on: 
Heroin: 1 bag costing €20 and containing on average 0.113g  
 at treatment intake, 1 bag containing on average 0.1g  
 costing €20 at 3-years.
Cocaine: 1 gram costing €110 at treatment intake, the same  
 quantity costing €70 at 3-years.
Cannabis: 1 ounce costing €110 at treatment intake, the  
 same quantity costing €198.45 at 3-years (or a joint  
 costing approximately 39c at treatment intake, and  
 approximately 70c at 3-years).
Source: Costs advised through private communication  
(O’Brien, An Garda Síochána).
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Table 4 shows the proportions that were drug free (not using 
any illegal drugs) as reported at treatment intake and at  
3-year follow-up. A significant increase in the proportions  
that were drug free is evident between treatment intake and 
3-years. Some opiate using clients were drug free at intake as 
they were recruited within the abstinence treatment modality.
Table 4:  Drug free at treatment intake and 3-years
Intake 3-years
Drug free in last 90 days % n % n
Drug free  
(not using any illicit drug ) 
9.3 37 29.4* 105
* denotes statistical significance. 
MORTALITy RATE
Of the 404 study participants recruited at intake, six had 
died by the time of the 3-year follow-up interview. This gives a 
mortality rate for the ROSIE study population at 3-year follow-up  
of 1.5% (95% C.I.: 0.5% - 3.2%)5. All of the deceased  
were male and ranged in age between twenty-six and  
fifty-two years. There was no single common cause of death 
amongst these participants. Two participants died from a drug 
overdose, two died as a result of a brain haemorrhage, one 
died in a road traffic crash and one participant was murdered. 
In terms of treatment modality, three of the deceased were 
recruited in the methadone modality, two were recruited 
in the detoxification modality and one was recruited in the 
needle-exchange modality.
INVOLVEMENT IN CRIME
Table 5 presents the proportion of individuals reporting 
participation in each category of crime at treatment intake 
and 3-year follow-up. Between intake and 3-years, a 
significant reduction in the proportion committing each  
type of crime, with the exception of theft from a vehicle  
and criminal damage, was observed.
Table 5:  Crimes committed at treatment intake 
and 3-years
Crime committed in the 
last 90 days
Intake 3-years
% n % n
Selling/supply drugs 30.0 109 12.6* 45
Theft from a person 10.8 39 1.7* 6
Theft from house/home 6.3 23 3.1* 11
Theft from shop/
commercial property
17.5 63 7.6* 27
Theft from a vehicle 6.1 22 3.7 13
Theft of a vehicle 6.0 22 1.7* 6
Handling stolen goods 25.3 91 10.4* 37
Fraud/forgery/deception 11.2 40 2.8* 10
Assault 8.1 29 2.8* 10
Criminal damage 7.2 26 3.1 11
Soliciting 3.9 14 0.6* 2
Breach of the peace 6.7 24 2.5* 9
* denotes statistical significance.
5  Two of the six deaths occurred within the 1-year follow-up period. The mortality rate for the population (2/404) at 1-year was 0.5%  
(95% C.I.: 0.06% - 1.78%).  
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INjECTING-RELATED RISK BEHAVIOUR 
Table 6 shows injecting drug use in the last 90 days as 
reported at treatment intake and at 3-year follow-up. Analysis 
shows significant reductions in the proportions injecting 
any drug, injecting heroin, injecting cocaine, and injecting 
benzodiazepines from treatment intake to 3-years.
Table 6:  Injecting drug use at treatment intake  
and 3-years
Intake 3-years
In the last 30 days % n % n
Injected any drug 44.0 177 27.5* 98
Injected heroin 41.6 168 25.3* 90
Injected cocaine powder 21.3 86 9.6* 34
Injected benzodiazepines 12.9 52 4.5* 16
* denotes statistical significance.
Table 7 displays the mean number of days injected and the 
mean number of times injected per day as reported at treatment 
intake and at 3-year follow-up. Analysis revealed significant 
reductions in both the mean number of days and the mean 
number of times injecting per day between intake and 3-years.
Table 7:  Mean days/times injecting at treatment 
intake and 3-years
Intake 3-years
In the last 30 days Mean (s.d.) Mean (s.d.)
Days injected 20.4 (32.2) 10.8 (25.9) *
Times injected on typical day 1.7 (3.7) 0.8 (1.8) *
* denotes statistical significance.
Table 8 presents data on injecting-related risk behaviour as 
reported at treatment intake and 3-years. At intake, a low 
proportion of participants reported injecting-related risk behaviour 
(i.e. the borrowing/lending of used injecting equipment). No 
significant changes were observed between treatment intake  
and 3-year follow-up for any injecting-related risk behaviour.
Table 8:  Injecting-related risk behaviour at 
treatment intake and 3-years
Intake 3-years
In the last 30 days % n % n
Borrowed used needle/
syringe 
5.6 21 3.4 12
Lent used needle/syringe 4.6 17 3.4 12
Re-used own needle/
syringe
15.7 52 16.0 55
Used filter/spoons after 
someone else
4.8 17 4.8 17
OVERDOSE
Table 9 presents data on overdoses within the last three 
months as reported at treatment intake and 3-years. The 
proportions did not change significantly between intake  
and 3-years.
Table 9:  Overdose at treatment intake and 3-years
Intake 3-years
In the last 90 days % n % n
Overdose 6.6 26 6.2 22
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PHySICAL AND MENTAL HEALTH 
OUTCOMES
Table 10 presents data on physical health symptoms 
experienced over the last 90 days as reported at treatment 
intake and at 3-years. Analysis revealed a significant decrease 
in proportions experiencing five symptoms (poor appetite, 
nausea/feeling sick, joint/bone pains, muscle pains, tremors/
shakes) between treatment intake and 3-years.
Table 10:  Number and proportion experiencing 
physical health symptoms at treatment intake 
and 3-years
Intake 3-years
Symptoms experienced 
over last 90 days
% n % n
Poor appetite 71.7 269 55.6* 194
Tiredness/fatigue 71.5 268 68.5 239
Nausea/feeling sick 39.8 148 32.6* 114
Stomach pains 39.8 148 36.5 127
Difficulty breathing 28.2 105 30.2 105
Chest pains 22.7 85 21.3 74
Joint/bone pains 36.0 135 27.3* 95
Muscle pains 32.7 122 22.0* 77
Numbness/tingling 22.6 84 27.4 95
Tremors/shakes 28.7 105 22.9* 80
* denotes statistical significance.
Table 11 presents data on mental health symptoms 
experienced over the last 90 days as reported at treatment 
intake and 3-years. Analysis revealed no significant 
differences in proportions experiencing any of the five anxiety 
symptoms between intake to treatment and 3-year follow-up.
In terms of depressive symptoms, there was a significant 
reduction in the proportions feeling hopeless about the 
future, feeling lonely and having thoughts of ending their 
lives between intake and 3-years.
Table 11:  Number and proportion experiencing 
mental health symptoms at treatment intake  
and 3-years
Symptoms experienced 
over last 90 days
Intake 3-years
% n % n
Anxiety symptoms
Feeling tense 65.2 234 67.3 231
Suddenly scared  
for no reason
35.6 129 35.3 122
Feeling fearful 42.3 149 47.4 163
Nervousness or  
shakiness inside
42.6 153 41.6 143
Spells of terror or panic 24.5 90 23.3 80
Depression symptoms
Feeling hopeless about  
the future
55.8 196 49.0* 169
Feeling of worthlessness 52.8 188 48.0 165
Feeling no interest in things 57.4 206 55.8 192
Feeling lonely 57.4 202 48.1* 165
Thoughts of ending own life 25.4 88 18.8* 65
* denotes statistical significance.

Authors: Dr Catherine Comiskey, Paul Kelly and Dr Robert Stapleton
October 2008Findings 6 : A summary of 3-year outcomes
TREATMENT STATUS
Table 12 shows the 3-year treatment status of participants.
Table 12:  Current treatment status of participants 
at 3-years
Current treatment status % n
In treatment at 3-years 68.9 246
Of those in treatment, proportion in 
methadone modality at 3-years
86.2 212
EMPLOyMENT, TRAINING AND 
ACCOMMODATION
Table 13 presents the proportions of individuals on training 
courses, currently employed, usually not working in the last 
three months, and employed at some time in the last three 
months as reported at treatment intake and 3-year follow-up. 
Analysis revealed a significant increase in the proportion of 
clients undertaking training courses over the last six months, 
currently employed, and employed at some point in the last 
three months between intake and 3-years. Finally, there was 
a significant reduction in the proportion of clients who were 
usually unemployed over the last three months between 
intake and 3-years.
Table 13:  Employment and training at treatment 
intake and 3-years
Intake 3-years
% n % n
Training courses over last 
six months
15.6 63 32.8* 117
Currently employed 16.0 64 28.7* 102
Employed at some point in 
last three months
21.3 84 30.1* 107
1Not working 42.9 171 30.5* 109
1 Refers to participants’ usual occupations over the last three 
months i.e. what their employment status was for most of  
the time.
* denotes statistical significance.
Table 14 shows participants’ accommodation during the 
previous three months as reported at treatment intake 
and 3-year follow-up. Analysis revealed a significant 
decrease in the proportion of participants who were taking 
up accommodation in the family home, drug treatment 
residences, and living in insecure tenure between intake 
and 3-years. These reductions were mirrored by significant 
increases in the proportion of candidates in their own house/
flat or rental accommodation.
Table 14:  Accommodation at treatment intake  
and 3-years
1Accommodation  
over last 90 days
Intake 3-years
% n % n
Family home 46.8 182 31.7* 113
Drug treatment 
residence
30.2 120 2.0* 7
Own house/flat or 
rental accommodation
33.8 134 49.0* 175
Prison 12.4 49 9.5 34
2Insecure tenure 10.2 40 8.4 30
3Homeless 14.7 58 11.2* 40
1  Categories are not mutually exclusive.
2 Insecure tenure refers to staying in home of friends. 
3 Homeless includes participants living in hostels, shelters,  
B&B’s or with no fixed abode.
* denotes statistical significance.
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SERVICE CONTACT
Table 15 presents the medical and social support service 
contact for participants as reported at treatment intake and 
3-year follow-up. Significant increases in the proportion 
attending a hospital and staying overnight, and the proportion 
visiting an out-patient department or receiving community 
treatment were evident between intake and 3-years.
In terms of social support service usage, significant increases 
were noted for both the proportions having contact about 
employment, training or education and the proportions 
having contact about housing issues between intake and  
3-years.
Table 15:  Contact with services at treatment 
intake and 3-years
Services received  
in last 90 days
Intake 3-years
% n % n
Attended hospital and 
stayed overnight 
8.7 34 15.7* 56
Attended Accident  
and Emergency
17.4 67 23.0 82
Visited a GP 33.6 124 39.2 140
Visited an out-patient 
department/received 
community treatment 
12.7 49 20.4* 73
Social support contacts  
in last 90 days
Had contact with  
social services 
6.4 25 9.8 35
Had contact about 
employment, training  
or education
10.4 37 32.2* 115
Had contact about  
social welfare
31.1 115 27.5 98
Had contact about  
housing issues 
14.7 55 26.9* 96
* denotes statistical significance.
Follow-up and interview rates of 97% and 88.4% 
respectively, obtained at 3-years from the full 
cohort of 404 recruited, were exceptionally high by 
international standards. In comparison, the National 
Treatment Outcome Research Study (NTORS) in 
England and Wales decided at 4-5 years to select 
a stratified random sub-sample of 650 participants 
from a sample frame of 894 individuals extracted 
from the full original cohort of 1077 recruits. Despite 
the use of this smaller sub-sample, the follow-up 
interview rate attained was 76.3% (496/650) 
(Gossop et al, 2003). ROSIE follow-up rates were 
also high in comparison with the Australian Treatment 
Outcome Study (ATOS), who achieved a follow-up 
interview rate of 76% (469/615) at 2-years (Darke 
et al, 2006). The achievement of a follow-up rate 
that is considerably higher than the international 
standard provides researchers with greater 
confidence in the final results observed for the  
ROSIE cohort at 3-years. 
Mortality rates within ROSIE were low in comparison 
with NTORS. Within NTORS at 4-years, 4.9% of 
those recruited are known to have died (Gossop 
et al, 2002). This was 6 times higher than the 
aged matched annual mortality rate of 1.2% 
within the general population. Within NTORS the 
majority (68%) of deaths were associated with 
drug overdoses. Within ROSIE, two of the six deaths 
(33%) within the 3-year follow-up period were 
known to be as a result of an overdose. Other 
international drug treatment studies include the 
Italian VEdeTTE study; a heroin users’ treatment 
outcome study with a recruited population of 10,454 
individuals. After 18 months, there had been 100 
deaths and after 30 months, there were 189 deaths 
out of a population of 10,258. This corresponds to a 
death rate of 12.0% (Schifano, 2006). The USA drug 
abuse treatment outcome study (DATOS) observed 
a 1-year mortality rate of 1.5% of the located 
population and a 5-year mortality rate of 7% of the 
located population (Hubbard et al, 2003). Due to 
study design and methodological differences, it is not 
appropriate to directly compare the mortality rates 
across these studies. However, they do provide an 
international context within which the ROSIE mortality 
rate data can be viewed.
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Results observed within the drug outcome measures 
were very encouraging. Reductions in the proportions 
using a range of target drugs were observed between 
intake and 3-years. Similar results were observed in both 
NTORS and ATOS. However, in addition, ROSIE observed 
significant reductions in the proportion reporting the use 
of alcohol from intake to 3-years. Within NTORS there 
were no statistically significant changes in alcohol use 
among either methadone or residential patients in either 
frequency or quantity consumed on a typical drinking 
day (Gossop et al, 2003). Similarly, no statistically 
significant changes in alcohol use were observed in 
ATOS (Darke et al, 2006). In contrast, within the ROSIE 
study the proportions of both frequency and quantity of 
alcohol used decreased significantly between intake and 
3-years. 
With regard to cocaine use, NTORS observed that 
outcomes for crack cocaine were not significantly 
different from intake (Gossop et al, 2003). In contrast 
ROSIE had significant reductions in the the reported 
use of both cocaine powder and crack cocaine from 
intake to 3-years. Furthermore, the proportion of ROSIE 
participants using benzodiazepines at 3-years was 
significantly lower than the proportion using at intake.
Finally, abstinence rates reported at 3-years by the 
ROSIE study were encouraging. Rates of abstinence 
from all illegal drugs increased significantly from intake 
to 3-years. NTORS abstinence rates are not directly 
comparable, as the authors report abstinence rates for 
methadone and residential treatment clients separately, 
while abstinence rates are computed for six target drugs 
only, and do not include cannabis. Within NTORS, 25.7% 
of those recruited within methadone were abstinent 
from the six drugs; heroin, non-prescribed methadone, 
non-prescribed benzodiazepines, crack cocaine and 
amphetamines at 4-5 years and 38% of those recruited 
within residential programs were abstinent from these  
six drugs at 4-5 years (Gossop et al, 2003). In 
comparison, within ROSIE, 42.9% of the followed-up 
cohort reported abstinence from these six particular 
target drugs at 3-years. 
With regard to crime outcomes, the ROSIE study 
reflected the outcomes observed in both NTORS and 
ATOS with significant reductions in crime observed at  
3-years.
In terms of health, the ROSIE study outcomes varied  
and no clear picture of health was observed, although 
at 3-years, significant reductions were observed in five 
of the 10 physical health symptoms measured. Within 
ATOS, significant improvements in health outcomes  
at 1-year were reported (Teesson et al, 2006), while 
NTORS reports reductions in mental health symptoms 
after 1-year among both residential and methadone 
patients. However authors note that among methadone 
patients there was an increase in symptoms between 
two and four/five years. Nonetheless, symptoms were 
still lower than intake levels (Gossop et al, 2003). None 
of the proportions in the ROSIE cohort experiencing the 
five anxiety symptoms decreased between intake and 
3-years. There were however reductions observed in the 
proportions experiencing three of the five depressive 
symptoms in the same time period. 
Overall, results indicate that in Ireland treatment for 
opiate use has a positive and sustaining effect, not  
only on drug use but on alcohol use, drug related 
crime and on social functioning variables. In addition, 
results on outcomes are not only comparable with other 
international outcome studies, but in some cases are 
better, particularly in terms of drug abstinence rates 
and the use of alcohol. However, while this is very 
encouraging, results also indicate that there is a clear 
need for more targeted, detailed research on long term 
physical and mental health outcomes for opiate users  
in treatment in Ireland.
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